candesartan has been researched along with Cardiomyopathies in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cardiomyopathic hearts showed significant increases in % fibrosis, % apoptosis, and myocyte diameter/body weight ratio; candesartan treatment reversed these changes." | 3.73 | Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. ( Aizawa, Y; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, S; Prakash, P; Soga, M; Tachikawa, H; Veeraveedu, P; Watanabe, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Majhi, S | 1 |
| Singh, L | 1 |
| Yasir, M | 1 |
| Susic, D | 1 |
| Varagic, J | 1 |
| Frohlich, ED | 1 |
| Soga, M | 1 |
| Kamal, FA | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Palaniyandi, S | 1 |
| Prakash, P | 1 |
| Veeraveedu, P | 1 |
| Mito, S | 1 |
| Kunisaki, M | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Yaras, N | 1 |
| Bilginoglu, A | 1 |
| Vassort, G | 1 |
| Turan, B | 1 |
4 other studies available for candesartan and Cardiomyopathies
| Article | Year |
|---|---|
Evaluation of Ameliorative Effect of Quercetin and Candesartan in Doxorubicin-Induced Cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Cardiomyopathies; Cardiotoxicity; Doxorubicin; H | 2022 |
Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2010 |
Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis | 2006 |
Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Caffeine; Calc | 2007 |